CSIMarket Company Name, Ticker, Industry, else..
 
Enveric Biosciences Inc   (NASDAQ: ENVB)
Other Ticker:  
 
 
Price: $1.6200 $-0.05 -2.994%
Day's High: $1.66 Week Perf: -6.36 %
Day's Low: $ 1.55 30 Day Perf: 37.29 %
Volume (M): 100 52 Wk High: $ 17.85
Volume (M$): $ 162 52 Wk Avg: $7.43
Open: $1.66 52 Wk Low: $0.41



 Market Capitalization (Millions $) 14
 Shares Outstanding (Millions) 9
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -10
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Enveric Biosciences Inc
Enveric Biosciences Inc. is a biotechnology company that focuses on developing and commercializing innovative therapies for patients suffering from cancer and other serious medical conditions. The company specializes in the research and development of cannabinoid-based pharmaceuticals, utilizing the therapeutic potential of cannabinoids to treat various symptoms and side effects of cancer treatments. Enveric Biosciences' goal is to improve the quality of life for patients by providing effective and safe treatments that address both physical and mental health aspects. The company is committed to conducting rigorous clinical trials and collaborating with healthcare professionals to bring their products to market.


   Company Address: 4851 Tamiami Trail N Naples 34103 FL
   Company Phone Number: 302-1707   Stock Exchange / Ticker: NASDAQ ENVB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AKBA   -5.88%    
AVDL   -5.77%    
CARA        7.34% 
EVOK        2.71% 
MRNS        0.62% 
SAGE        6.42% 
• View Complete Report
   



Business Update

Enveric Biosciences Charts Ambitious Course Amidst Market Challenges with New Patent for Neurotherapeutics

Published Wed, Feb 26 2025 8:06 AM UTC

Enveric Biosciences (NASDAQ: ENVB), a pioneering biotechnology firm rooted in Cambridge, Massachusetts, has recently made significant strides in its mission to develop innovative small-molecule therapeutics aimed at combating depression, anxiety, and addiction disorders. On January 14, 2025, the United States Patent and Trademark Office issued U.S. Patent No. 12,195,439, an ...
Business Update

Enveric Biosciences Secures Patent for Revolutionary EVM401 Compounds Targeting Mental Health Disorders,

Published Tue, Feb 25 2025 9:53 PM UTC

In a significant step towards revolutionizing the treatment landscape for mental health disorders, Enveric Biosciences (NASDAQ: ENVB) has received a U.S. patent for its EVM401 series of compounds. This development signals a promising advancement in the realm of biopharmaceuticals aimed at combating depression, anxiety, and addiction-related conditions. The issuance of U.S. ...
Business Update

?Unlocking Neuroplasticity Enveric Biosciences? EB-003 Emerges as a Beacon of Hope for Mental Health Tre...

Published Fri, Jan 31 2025 10:19 AM UTC

Abstract: Enveric Biosciences, a biotechnology company focused on innovative small-molecule therapeutics targeting neuroplasticity, has made significant strides in the development of its lead drug candidate, EB-003. Recent announcements include a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO) and comprehensive preclinical pharmacokinet...
Business Update

Enveric Biosciences Secures Key Patents amid Market Struggles A Balancing Act between Innovation and Investor Confide...

Published Mon, Dec 2 2024 2:47 PM UTC

Enveric Biosciences: Navigating A New Patent Milestone Amidst Market Challenges In a landscape characterised by dynamic shifts and competitive forces, Enveric Biosciences (NASDAQ: ENVB), a Cambridge-based biotechnology firm, has remarkably succeeded in securing additional intellectual property protections. Recently, the United States Patent and Trademark Office (USPTO) grant...
Business Update

Enveric Biosciences Breakthroughs in Neuroplastogen Therapy with Non-Hallucinogenic EB-003,

Published Mon, Nov 25 2024 2:47 PM UTC

Enveric Biosciences? EB-003 Exhibits Promising Preclinical Results in Oral Bioavailability and Brain Penetration Paving the Path for Next-Generation Neuroplastogen TherapeuticsRecent advancements in biotechnology have paved the way for innovative treatments aimed at addressing critical mental health challenges such as depression, anxiety, and various psychiatric disorders. ...









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com